Antidepressant for the prevention of DEPression following first episode Psychosis trial - ADEPP

niversity of Birmingham0 sites508 target enrollmentSeptember 16, 2020

Overview

No summary available.

Registry

who.int

Start Date

September 16, 2020

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•Diagnosis of first\-episode psychosis (FEP).
•Within 3 months of initial treatment for FEP (as defined by onset of care provision by an Early Intervention Team).
•Positive and Negative Syndrome Scale (PANSS) individual positive item scores all \= 4\.
•Sufficiently recovered from acute psychotic episode with capacity to consent.
•Aged 18\-35 years.
•Currently prescribed antipsychotic medication at stable dose.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 508

•Current moderate or severe depression (as indicated by a Calgary Depression for
•Schizophrenia Scale (CDSS) score of \>7\).
•Currently prescribed antidepressant medication (or within 2 weeks of stopping if a Monoamine Oxidaise Inhibitor)
•Previous history of mania.
•Contraindications to selective serotonin reuptake inhibitors (SSRI) antidepressant treatment (e.g. recurrent thrombotic illness, previous adverse reaction, confirmed pregnancy, although risk in pregnancy is low, prescribed pimozide).
•Serious medical or neurological illness (as identified by the treating consultant psychiatrist).
•Electrocardiogram (ECG): QTc interval \>450 as measured in the last 12 months.
•Aged below 18 years
•Aged over 35 years